These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 18279055)
1. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Mori K; Ando K; Heymann D Expert Rev Anticancer Ther; 2008 Feb; 8(2):151-9. PubMed ID: 18279055 [TBL] [Abstract][Full Text] [Related]
2. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249 [TBL] [Abstract][Full Text] [Related]
3. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Anderson P Future Oncol; 2006 Jun; 2(3):333-43. PubMed ID: 16787112 [TBL] [Abstract][Full Text] [Related]
4. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. Meyers PA; Chou AJ Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714 [TBL] [Abstract][Full Text] [Related]
6. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Chou AJ; Kleinerman ES; Krailo MD; Chen Z; Betcher DL; Healey JH; Conrad EU; Nieder ML; Weiner MA; Wells RJ; Womer RB; Meyers PA; Cancer; 2009 Nov; 115(22):5339-48. PubMed ID: 19637348 [TBL] [Abstract][Full Text] [Related]
7. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Kleinerman ES; Maeda M; Jaffe N Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644 [TBL] [Abstract][Full Text] [Related]
9. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. Kleinerman ES; Snyder JS; Jaffe N J Clin Oncol; 1991 Feb; 9(2):259-67. PubMed ID: 1988574 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921 [TBL] [Abstract][Full Text] [Related]
11. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542 [TBL] [Abstract][Full Text] [Related]
12. Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma. Meyers PA Adv Exp Med Biol; 2020; 1257():133-139. PubMed ID: 32483736 [TBL] [Abstract][Full Text] [Related]
13. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. MacEwen EG; Kurzman ID; Helfand S; Vail D; London C; Kisseberth W; Rosenthal RC; Fox LE; Keller ET; Obradovich J J Drug Target; 1994; 2(5):391-6. PubMed ID: 7704483 [TBL] [Abstract][Full Text] [Related]
14. Mifamurtide in osteosarcoma--a practical review. Anderson PM; Tomaras M; McConnell K Drugs Today (Barc); 2010 May; 46(5):327-37. PubMed ID: 20517534 [TBL] [Abstract][Full Text] [Related]
15. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Ando K; Mori K; Corradini N; Redini F; Heymann D Expert Opin Pharmacother; 2011 Feb; 12(2):285-92. PubMed ID: 21226638 [TBL] [Abstract][Full Text] [Related]
16. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Kurzman ID; Shi F; Vail DM; MacEwen EG Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295 [TBL] [Abstract][Full Text] [Related]
18. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. Asano T; Kleinerman ES J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710 [TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE. Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500 [TBL] [Abstract][Full Text] [Related]
20. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma. Kleinerman ES; Jaffe N Prog Clin Biol Res; 1990; 343():263-79. PubMed ID: 2198583 [No Abstract] [Full Text] [Related] [Next] [New Search]